Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H32N2O2.C4H6O6 |
| Molecular Weight | 542.6206 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]([C@H](O)C(O)=O)C(O)=O.C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=ACRMUSVWIFZVSM-AEABCVGESA-N
InChI=1S/C25H32N2O2.C4H6O6/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27;5-1(3(7)8)2(6)4(9)10/h2-7,10-13,21H,8-9,14-20H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t21-;1-,2-/m10/s1
| Molecular Formula | C25H32N2O2 |
| Molecular Weight | 392.5338 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H6O6 |
| Molecular Weight | 150.0868 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1959-01-01_4_page004.htmlCurator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=G7As-qawdzMC&printsec=frontcover&hl=ru#v=onepage&q&f=false | https://www.cbg-meb.nl/documenten/rapporten/2015/09/14/par-dextromoramide | https://medikamio.com/nl-nl/geneesmiddelen/palfium-tablet-5-mg/pil
Sources: https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1959-01-01_4_page004.html
Curator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=G7As-qawdzMC&printsec=frontcover&hl=ru#v=onepage&q&f=false | https://www.cbg-meb.nl/documenten/rapporten/2015/09/14/par-dextromoramide | https://medikamio.com/nl-nl/geneesmiddelen/palfium-tablet-5-mg/pil
Dextromoramide is a synthetic strong-acting opioid and full mu-opioid receptor agonist. Dextromoramide is a Schedule I drug illegal to possess. The current indication for Palfium® (dextromoramide) is severe acute or chronic pain requiring opioids, such as post-operative pain, and pain associated with bone fractures, malignancies and acute renal/biliary colic attacks in adults.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PALFIUM Approved UsePalfium® (dextromoramide) is a synthetic strong-acting opioid and full mu-opioid receptor agonist that has been registered in the Netherlands since 1974. The current indication is severe acute or chronic pain requiring opioids, such as post-operative pain, and pain associated with bone fractures, malignancies and acute renal/biliary colic attacks in adults. Launch Date1973 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:24:30 GMT 2023
by
admin
on
Fri Dec 15 17:24:30 GMT 2023
|
| Record UNII |
SQR8W22C2V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SQR8W22C2V
Created by
admin on Fri Dec 15 17:24:30 GMT 2023 , Edited by admin on Fri Dec 15 17:24:30 GMT 2023
|
PRIMARY | |||
|
25115416
Created by
admin on Fri Dec 15 17:24:30 GMT 2023 , Edited by admin on Fri Dec 15 17:24:30 GMT 2023
|
PRIMARY | |||
|
23071-04-7
Created by
admin on Fri Dec 15 17:24:30 GMT 2023 , Edited by admin on Fri Dec 15 17:24:30 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
